Wednesday December 8, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET Join this webinar to learn how to approach the early stages of drug development and build a long-term plan to advance your drug to market.
Biotech and biopharma companies continue to drive the drug development pipeline, and despite a global pandemic, many small, nimble sponsors remain strong in funding levels and drug approvals. Still, with increased investment in the biotech sector, competition for visibility and resources is fierce.
For many small sponsors, the number of questions to ask and decisions to make can be overwhelming. Leveraging data and expertise to support a strategic drug development plan can mean the difference between success and failure.
Join this webinar to learn how to approach the early stages of drug development and build a long-term plan to advance your drug to market.
Key Learning Objectives:
Chief Operating Officer
Megan Hooton brings a wealth of operational and cross-cultural expertise to the role of Chief Operating Officer at IQVIA Biotech, having more than 30 years of experience managing global research and development operations across pharmaceutical and biotech segments.
Meg joined IQVIA in 2008 and has served in clinical operations and project management roles, initially in her native Australia, and later managed the North Asia Therapeutic Delivery Unit. She served as Vice President and Head of Global Project Leadership and Regulatory Start-up for the Asia-Pacific region before becoming the Global Therapeutic Area Head for Oncology in 2017.
Meg started her career as a Registered Nurse, and after stints in the private sector, academia, and the Royal Australian Navy Reserve, she joined the clinical team at Bristol-Myers Squibb in the oncology and immunology franchises. In addition to her nursing degree and specialization in Intensive Care and Coronary Care, Meg has a bachelor's degree in Asian Studies from Monash University.
Vice President and Global Head of the Strategic Drug Development Group
Michael Kardas, PharmD is Vice President and Global Head of the Strategic Drug Development Group at IQVIA. Dr. Kardas has more than 20 years of experience in the biopharma industry and provides expert advice to biopharmaceutical companies in the data driven design and development of their clinical program. He earned his B.A. degree in Biology from College of the Holy Cross and completed his Doctor of Pharmacy degree from the University of Connecticut.